Kissei Pharmaceutical Co., Ltd.

4547

JP3240600001

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-25 am EDT			5-day change	1st Jan Change
3,535 ^JPY	-1.12%		+0.28%	+14.40%

Mar. 20	Kissei Pharmaceutical Completes 6 Billion Yen Buyback Program	MT
Mar. 19	Tranche Update on Kissei Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 8, 2023.	CI

Kissei Pharmaceutical Co., Ltd. authorizes a Buyback Plan.

March 03, 2021

The Board of Directors of Kissei Pharmaceutical Co., Ltd. has authorized a buyback plan on March 4, 2021.

Latest news about Kissei Pharmaceutical Co., Ltd.

Kissei Pharmaceutical Completes 6 Billion Yen Buyback Program	Mar. 20	MT
Tranche Update on Kissei Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 8, 2023.	Mar. 19	CI
Kissei Pharmaceutical Co., Ltd.'s Equity Buyback announced on May 8, 2023, has closed with 1,909,900 shares, representing 4.18% for ¥5,999.99 million.	Mar. 17	CI
Kissei Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 2024	Jan. 30	CI
Kissei Pharmaceutical Repurchases 251 Million Yen Worth of Shares in December 2023	Jan. 04	MT
Tranche Update on Kissei Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 8, 2023.	Jan. 04	CI
Kissei and Maruishi Debut Injection for Dialysis-Related Itching	Dec. 12	MT
Kissei Pharmaceutical Co., Ltd. and Maruishi Pharmaceutical Co., Ltd. Announces KORSUVA®? IV Injection Syringe for Dialysis 17.5ug, 25.0ug to Launch in Japan for Treatment of Pruritus in Patients Undergoing Hemodialysis	Dec. 12	CI
Japanese Shares Close Lower on Tuesday After Key Economic Data	Nov. 07	MT
Kissei Pharmaceutical's Fiscal H1 Attributable Profit Surges as Net Sales Gains	Nov. 07	MT
Kissei Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024	Nov. 06	CI
Kissei Pharmaceutical Co., Ltd. Announces Second Quarter-End Dividend for the Year Ending March 31, 2024, Payable on December 4, 2023 and Provided Dividend Guidance for the Year Ending March 31, 2024	Nov. 06	CI
Jefferies Downgrades Kissei Pharmaceutical to Hold From Buy, Adjusts Price Target to 3,400 Yen From 3,300 Yen	23-10-30	MT
Kissei Pharmaceutical Co., Ltd. Revises Consolidated Earnings Guidance for the First Half Ending September 30, 2023	23-10-27	CI
Tranche Update on Kissei Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 8, 2023.	23-10-02	CI
Kissei Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2024	23-07-31	CI
Kissei Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending March 31, 2024	23-07-31	CI
Kissei Pharmaceutical Withdraws Marketing Approval Application for Rovatirelin	23-07-19	MT
Kissei Pharmaceutical Co., Ltd. Announces Withdrawal of Application for Marketing Approval for Rovatirelin for the Treatment of Spinocerebellar Degeneration in Japan	23-07-19	CI
Kissei Pharmaceutical Co., Ltd. Introduces Iktos AI Drug Discovery System	23-07-03	CI
Tranche Update on Kissei Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 8, 2023.	23-07-03	CI
The Hachijuni Bank, Ltd. completed the acquisition of the remaining 98.33% stake in The Naganobank, Ltd. from The Master Trust Bank of Japan, Ltd. (Trust Account), Custody Bank of Japan, Ltd. (Trust Account), The Tochigi Bank, Ltd., Kissei Pharmaceutical Co., Ltd.,Sompo Japan Insurance Inc. and others.	23-05-31	CI
Kissei Pharmaceutical's Full-Year Profit Falls 18.5%	23-05-10	MT
Kissei Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending March 31, 2024	23-05-09	CI
Kissei Pharmaceutical Co., Ltd. Announces Dividend for the Year Ended March 31, 2023, Payable on June 23, 2023; Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2024	23-05-09	CI

Chart Kissei Pharmaceutical Co., Ltd.

Duration

Period

More charts

KISSEI PHARMACEUTICAL CO.,LTD. is a Japan-based company mainly engaged in the manufacture and sale of pharmaceutical products. The Company is engaged in the collection and analysis of medicine development information, and the manufacture and sale of medicines. It is also engaged in the purchase and sale of related materials, system development and information process work, construction contract work such as new construction, expansion and renovation of factories, laboratories and offices, the management of facility and equipment work, information collection and development support work, noodle manufacture and sale, and insurance agency business.

Sector

Pharmaceuticals

Calendar

2024-05-06 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Kissei Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

3,535 JPY

Average target price

3,833 JPY

Spread / Average Target

+8.44%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
KISSEI PHARMACEUTICAL CO., LTD.	+14.40%	1.02B
MERCK KGAA	+4.16%	70.78B
KYOWA KIRIN CO. LTD.	+10.72%	9.15B
SK BIOPHARMACEUTICALS CO., LTD.	-17.03%	4.84B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+37.51%	4.22B
YUHAN CORPORATION	+3.92%	3.92B
INDIVIOR PLC	+18.14%	2.55B
BETTA PHARMACEUTICALS CO., LTD.	-24.13%	2.26B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29.70%	2.24B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+9.09%	1.92B

Specialty & Advanced Pharmaceuticals